JS014 + pembrolizumab

JS014 + pembrolizumab is an investigational combination therapy comprising JS014, a recombinant fusion protein of interleukin-21 and a humanized anti-human serum albumin nanobody, together with pembrolizumab, a monoclonal antibody targeting programmed cell death protein 1 (PD-1). JS014 is designed to enhance anti-tumor immunity by prolonging IL-21 activity and boosting immune responses. Pembrolizumab acts as a checkpoint inhibitor, blocking the PD-1/PD-L1 interaction to release immune inhibition and enable T cell-mediated anti-tumor activity. The combination seeks to synergize immune activation by both stimulating and releasing immune brakes. Clinical development focuses on advanced cancers, with ongoing phase 1 trials evaluating safety, pharmacokinetics, and preliminary efficacy[1].

Other names

Recombinant interleukin-21-anti-human serum albumin nanobody fusion protein + pembrolizumabJS014 + Keytruda